Portfolio

VectorY

CEO Sander van Deventer

An integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for CNS diseases.

Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.

VectorY will develop proprietary & partnered programs based on novel AAV-based vectorized antibody gene therapy technologies. Forbion has provided seed financing to the company and is closely involved with the operational business and strategy.

Human Health

Science Park
Matrix Innovation Center 408
1098 HX Amsterdam

vectorytx.com

Industry

Biotech

Status

Current

Location

The Netherlands

I've had an opportunity to work with a wide array of investors throughout a lengthy career leading innovative private and public US-based biotech companies. As CEO of VectorY Therapeutics, it's been an eye-opening and fantastic experience working with Forbion, which has a unique value proposition in the biotech ecosystem. On a daily basis Forbion exhibits its deep commitment to VectorY, well beyond its vast capital commitments. Forbion's sizeable, collaborative and experienced investing team and advisory network bring expansive and profound insights into our company and value building process.

Jim Scibetta

CEO